C3 GLOMERULOPATHY (C3G)
Clinical trials for C3 GLOMERULOPATHY (C3G) explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY (C3G) trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood and kidney diseases: early access to iptacopan
Disease control AVAILABLEThis program offers early access to the drug iptacopan for people with serious conditions like C3 glomerulopathy (a kidney disease) or paroxysmal nocturnal hemoglobinuria (a blood disorder) who have no other treatment options. Doctors can request the drug for patients who are not…
Matched conditions: C3 GLOMERULOPATHY (C3G)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New kidney drug CPV-104 tested in humans for first time
Knowledge-focused Recruiting nowThis early-stage study tests CPV-104, a new medicine for C3 glomerulopathy (C3G), a rare kidney disease. Healthy volunteers get one dose, and C3G patients get four weekly doses to check safety and how the body handles the drug. The main goal is safety, not effectiveness, and a sa…
Matched conditions: C3 GLOMERULOPATHY (C3G)
Phase: PHASE1 • Sponsor: eleva GmbH • Aim: Knowledge-focused
Last updated May 17, 2026 00:42 UTC